Ibrutab 140 mg (Capsule)
Unit Price: ৳ 600.00 (2 x 14: ৳ 16,800.00)
Strip Price: ৳ 8,400.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Ibrutinib |
| Company | Eskayef pharmaceuticals ltd |
Indications
- Mantle Cell Lymphoma
- Chronic Lymphocytic Leukemia
- Waldenstrom Macroglobulinemia
- Marginal Zone Lymphoma
Pharmacology
- BTK inhibitor
- Covalent bond formation
- Enzymatic activity inhibition
- B-cell antigen receptor signaling
- Cytokine receptor pathway inhibition
- B-cell trafficking
- Chemotaxis and adhesion inhibition
- Malignant B-cell proliferation inhibition
- Cell migration and substrate adhesion inhibition
Dosage
- Recommended daily dose for Mantle Cell Lymphoma and Marginal Zone Lymphoma
- Recommended daily dose for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Waldenstrom Macroglobulinemia
- Additional recommended dose for CLL/SLL in combination with bendamustine and rituximab
Administration
- Oral administration
- Once daily administration
- Swallow whole with water
- Do not open, break, or chew the capsules
Interaction
- Avoid co-administration with CYP3A inhibitors
- Dose reduction with moderate CYP3A inhibitor usage
- Avoid co-administration with strong CYP3A inducers
Contraindications
- Hypersensitivity to the active substance or excipients
Side Effects
- Hemorrhage
- Infections
- Cytopenias
- Atrial Fibrillation
- Hypertension
- Second Primary Malignancies
- Tumor Lysis Syndrome
- Diarrhea
- Visual Disturbance
Pregnancy & Lactation
- Fetal harm potential
- No information on effects on breastfed infant or milk production
Use in Special Populations
- Lack of established use in pediatric patients
- Effectiveness in geriatric patients
- Hepatic impairment safety and efficacy evaluation
Overdose Effects
- No specific management experience
- Potential reversible hepatic enzyme increases
Therapeutic Class
- Targeted Cancer Therapy
Storage Conditions
- Store below 30°C
- Protect from light
- Keep out of reach of children